UBS analysts reaffirmed a high success probability for Ocular Therapeutix's wAMD drug Axpaxli, despite a competitor's trial failure. This suggests continued confidence in the underlying drug mechanism and potentially strengthens Ocular Therapeutix's market position in the wAMD space.
UBS analysts maintained a 75% success probability for Ocular Therapeutix's Axpaxli, a drug for wet AMD. This positive outlook comes despite the recent failure of EyePoint Pharmaceuticals' competing drug, Duravyu, in late-stage trials. The filing indicates that Ocular Therapeutix management believes the competitor's failure still supports the biologic activity of the tyrosine kinase inhibitor mechanism, which is central to their own development. This development is a short-term positive for OCUL, as it reduces competitive pressure and validates their drug's mechanism, potentially increasing investor confidence. For EYPT, it's a clear negative, highlighting the risks of drug development. The long-term implication for OCUL is a potentially clearer path to market if Axpaxli succeeds, while EYPT faces significant setbacks. Traders should note the reduced competitive landscape for OCUL and the increased pressure on EYPT.